---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-270358"
form_type: "8-K"
ticker: "NTLA"
cik: "0001652130"
company_name: "Intellia Therapeutics, Inc."
filed_at: "2026-06-15T12:52:21+00:00"
generated_at: "2026-06-15T12:55:08.712494+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Intellia reports positive Phase 3 HAELO results for lonvo-z; BLA rolling submission initiated

## Summary
- 89% reduction (p<0.0001) in monthly attacks requiring on-demand treatment vs placebo; 91% reduction in moderate/severe attacks.
- 62% of lonvo-z patients attack-free and therapy-free during weeks 5-28 vs 11% placebo (p<0.0001).
- AE-QoL total score improved by -17.04 points vs placebo (p<0.0001); all TEAEs mild/moderate, no serious events in lonvo-z arm.
- Rolling BLA submission started April 2026; company expects FDA approval and U.S. launch in first half 2027.
- All patients in lonvo-z arm experienced attack-rate reductions; plasma kallikrein levels stable through Feb 2026 cutoff.

## SEC filing metadata
- accession: 0001193125-26-270358
- form_type: 8-K
- ticker: NTLA
- cik: 0001652130
- company_name: Intellia Therapeutics, Inc.
- filed_at: 2026-06-15T12:52:21+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/0001193125-26-270358-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1652130/000119312526270358/ntla-20260613.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-270358
- JSON: https://secwatch.observer/filing/0001193125-26-270358.json
- Plain text: https://secwatch.observer/filing/0001193125-26-270358.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.